A look at Eli Lilly

Eli Lilly (LLY) is a US-based multinational pharmaceutical company headquartered in Indianapolis. Its product portfolio includes human pharmaceuticals and animal health products. The company reported 9% YoY (year-over-year) growth in its top line to ~$5.7 billion for 3Q17.

Inside Eli Lilly’s Revenue Trends in 3Q17

Eli Lilly surpassed the Wall Street analysts’ 3Q17 revenue estimate of ~$5.5 billion as well as the EPS (earnings per share) estimate of $1.03, reporting $1.05 for the latest quarter.

Stock performance

LLY stock has risen ~10.1% over the past 12 months and 13.8% YTD (year-to-date). Its top-line increase was driven by the strong performance of human pharmaceuticals and animal health products. It reported net income of $1.1 billion for 3Q17, which was 19% higher YoY.

US markets contributed ~54.8% of LLY’s total revenues in 3Q17 at $3.1 billion, which was a 9% YoY rise, due to the increased sales of Basaglar, Jardiance, Lartruvo, Taltz, and Trulicity, and companion animal products including the acquired portfolio of US feline, canine, and rabies vaccines acquired from Boehringer Ingelheim.

The contribution from outside the US was ~45.1% of total 3Q17 revenues at ~$2.6 billion, which was 8% higher YoY and mainly driven by Humalog and Forteo sales.

Notably, the Health Care Select Sector SPDR ETF (XLV) has 2.6% of its total portfolio in Eli Lilly (LLY). XLV also has 1.9% in Allergan (AGN), 3.0% in Gilead Sciences (GILD), and 2.1% in Biogen (BIIB).

Latest articles

The future of the T-Mobile and Sprint merger remains unclear. Several state attorneys and Democratic senators have come together to oppose it.

According to President Trump, the US economy is “poised for big growth after trade deals are completed.” Markets are volatile amid the trade war.

Canopy Growth didn't impress investors with its earnings for the first quarter of 2020. The stock has fallen 12.4% since the company's earnings.

President Trump finally seems to acknowledge how the US-China trade war could impact tech giant Apple. Trump met with Apple CEO Tim Cook at a dinner.

As of August 13, HEXO (HEXO) was trading at 6.51 Canadian dollars—a fall of 30.9% since its third-quarter earnings on June 12.

On August 15, in an interview with CNBC, Mark Zandi said that the trade war hurts the US economy. The trade war has a negative impact on certain sectors.